ACE-031 (also called ramatercept) is a recombinant soluble decoy receptor built from the extracellular ligand-binding domain of the human activin type IIB receptor (ActRIIB, gene ACVR2B) fused to the Fc region of human IgG1, and it is used in laboratory research as a ligand trap for myostatin (GDF-8), GDF-11, and activins that signal through ActRIIB. Because it circulates as a disulfide-linked homodimer of two ActRIIB-Fc monomers, published analytical work places the reduced monomer near 58 kDa and the assembled dimer well above 90 kDa — it is a fusion protein, not a short synthetic peptide. Clinical development by Acceleron Pharma was halted in 2013 after non-muscle vascular adverse events, and as of 2026 ACE-031 exists only as a research reagent and a well-characterized tool for probing the ActRIIB–SMAD2/3 axis. This article reviews its origin, mechanism, the published experimental record, the identity/purity problem documented in third-party analyses of research-channel material, and laboratory handling.
All content below is provided strictly for in-vitro and laboratory research context. Nothing here describes or endorses any human or veterinary use.
What Is ACE-031?
The scientific story begins in 1997, when a Nature paper described a new TGF-β superfamily member, growth/differentiation factor-8 (GDF-8, later named myostatin), expressed almost exclusively in skeletal muscle. Mice lacking the gene developed roughly two to three times normal skeletal muscle mass, establishing myostatin as a negative regulator of muscle growth — a brake rather than an accelerator. That single observation launched two decades of work aimed at releasing the brake pharmacologically.
The decoy-receptor strategy came out of that effort. Rather than neutralizing myostatin with an antibody, researchers reasoned that a soluble version of the receptor myostatin binds — ActRIIB — would sequester the ligand before it reached cell-surface receptors. A 2005 PNAS study tested exactly this: a soluble ActRIIB construct produced increases in murine muscle mass of up to about 60% within two weeks. Critically, the same study found that the effect was attenuated but not abolished in myostatin-null mice, indicating that ActRIIB traps capture more than one ligand. This multi-ligand behavior — myostatin plus activins and GDF-11 — is the defining pharmacological feature of the class, and it explains both its potency and its off-target profile.
ACE-031 is the clinical-grade engineering of that concept: ActRIIB extracellular domain + IgG1 Fc, expressed recombinantly, dimerized through the Fc hinge.
ACE-031 is not a peptide
This point matters for anyone sourcing or characterizing material. Research catalogs frequently list ACE-031 alongside short synthetic peptides such as BPC-157 or ipamorelin, and some listings carry molecular weights in the low-thousands of daltons that are inconsistent with the published literature. Authentic ACE-031 is a glycosylated recombinant fusion protein. A 2025 analytical study in Drug Testing and Analysis reported the main immunoreactive band of research-channel material at approximately 58.4 kDa under reducing conditions — an order of magnitude larger than any synthetic peptide. Any characterization plan built around peptide assumptions (simple RP-HPLC purity, small-molecule MS) will not adequately describe this molecule.
Mechanism of Action
Myostatin and related ligands signal by binding a type II receptor (ActRIIA or ActRIIB), which then recruits and phosphorylates a type I receptor (ALK4 or ALK5). The activated type I receptor phosphorylates SMAD2 and SMAD3, which complex with SMAD4, translocate to the nucleus, and drive a transcriptional program that suppresses myofiber protein accretion — in part by antagonizing IGF-1/Akt/mTOR-driven protein synthesis and by restraining satellite-cell activity.
ACE-031 intervenes at the first step. As a soluble ActRIIB ectodomain, it competes with membrane-bound ActRIIB for ligand:
- Ligand capture. Extracellular myostatin, GDF-11, activin A and related ligands are bound by the decoy and cannot engage cell-surface receptors.
- Loss of SMAD2/3 phosphorylation. Downstream signaling falls, de-repressing the anabolic program in muscle.
- Fc-driven persistence. The IgG1 Fc domain confers FcRn-mediated recycling, giving the construct a long circulating half-life relative to the native ectodomain — which is why in-vivo study designs use dosing intervals of weeks rather than hours.
What the Published Studies Show
Rodent models
Soluble ActRIIB constructs are among the most reproducible hypertrophy tools in the muscle-biology literature. Beyond the ~60% two-week mass increase reported in wild-type mice, the class has been characterized in aged rodents, where ActRIIB-Fc treatment increased hindlimb muscle mass and force production alongside gains in bone mineral density and bone-formation markers. In the mdx mouse model of Duchenne muscular dystrophy, a 2017 study in BMC Musculoskeletal Disorders reported that soluble ActRIIB receptor treatment improved bone mass and mechanical strength — evidence that the axis is not muscle-exclusive and that skeletal effects are part of the phenotype.
Non-human primates (2026)
The most recent primary data are from February 2026. A study in PLOS ONE administered ACE-031 or vehicle to common marmosets (Callithrix jacchus) over a 14-week randomized protocol with weekly body-composition measurement. Treated animals showed a significant increase in lean body mass from baseline that vehicle controls did not; histomorphometry of biceps brachii found increased cross-sectional area in both type I and type II fibers; and ex-vivo contractile testing showed increases in both absolute and specific force. The specific-force result is notable because a recurring criticism of myostatin-pathway hypertrophy is that added mass may not be proportionally functional — here, force normalized to cross-sectional area rose rather than fell.
Human clinical program (halted 2013)
Two published trials define the clinical record.
A single ascending-dose phase 1 study (Muscle & Nerve, 2013) randomized 48 healthy postmenopausal women 3:1 to a single subcutaneous administration of ACE-031 or placebo across an escalating series of exposure levels. At day 29, MRI-measured thigh muscle volume rose approximately 3.7% and 5.3% over placebo in the two highest exposure arms, with total lean mass increasing about 3.3% in the top arm. These figures are reported here only as historical trial outcomes; no exposure levels for any living subject are provided or implied by this article.
A phase 2 randomized, double-blind, placebo-controlled multiple ascending-dose trial in ambulatory boys with Duchenne muscular dystrophy (Muscle & Nerve, 2017) administered ACE-031 subcutaneously every 2–4 weeks. The study was stopped after the second dosing regimen because of epistaxis (nosebleeds) and telangiectasias — dilated small blood vessels. No serious or severe adverse events were reported, and non-statistically-significant trends favored the treated groups on 6-minute walk distance, lean body mass, bone mineral density, and fat mass. The authors concluded that non-muscle-related adverse events drove the discontinuation.
The interpretive consensus in later reviews is that these vascular events reflect the ligand promiscuity described above rather than a failure of the myostatin hypothesis itself. A 2021 review in International Journal of Molecular Sciences framed the broader field bluntly: strong preclinical results across many antimyostatin modalities have repeatedly failed to translate into clinical benefit, and understanding why remains an open research question. Subsequent programs shifted toward more selective agents — myostatin-specific antibodies, ActRIIA/IIB-selective constructs — precisely to avoid the BMP9/10 interaction.
The Identity and Purity Problem
A 2025 study in Drug Testing and Analysis provides the most directly relevant purity data for anyone working with material obtained through research-supply channels. Investigators analyzed 14 products sold as ACE-031 using SDS-PAGE, Western blotting, mass spectrometry, and IdeS protease digestion. Findings:
- Only 12 of 14 products contained any ACVR2B-immunoreactive protein at all.
- All 12 positives contained numerous additional proteins beyond the main ~58.4 kDa band.
- Mass spectrometry and immunoblotting indicated the material was full-length human activin receptor IIB, not the ACE-031 Fc-fusion construct.
- IdeS protease — which cleaves IgG below the hinge — failed to cut the products, confirming the absence of an Fc fusion.
Laboratory Handling and Storage
Handling for a recombinant Fc-fusion protein differs meaningfully from handling a lyophilized synthetic peptide:
- Storage of lyophilate. Typically −20 °C or below, desiccated and protected from light. Long-term storage of reconstituted protein is generally recommended at −80 °C.
- Reconstitution. Sterile water or an appropriate buffer, added slowly down the vial wall. Fusion proteins are sensitive to shear and interfacial stress — do not vortex; swirl gently and allow the solid to dissolve without foaming.
- Freeze–thaw. Aliquot on first reconstitution. Repeated freeze–thaw cycles promote aggregation in Fc-fusion proteins, and aggregates alter both apparent potency and immunoassay behavior.
- Aggregation checks. Where quantitative results matter, size-exclusion chromatography or dynamic light scattering on the working stock is worthwhile; a protein that has aggregated will still show protein content but will not behave as a monodisperse decoy receptor.
- Adsorption. At low working concentrations, protein loss to plastic is real. Carrier protein (e.g., BSA) in dilution buffer is standard practice for in-vitro assays.
Freshness Note (2026)
As of August 2026, ACE-031 has no active clinical development program; the Acceleron program ended in 2013 and no subsequent sponsor has revived it. The newest primary data are the February 2026 PLOS ONE marmoset study described above, which is the first non-human-primate efficacy dataset for the compound and reports fiber-type-independent hypertrophy with preserved specific force. Interest in the broader ActRII/myostatin axis has increased over 2024–2026 in connection with academic research into how skeletal muscle mass is regulated during incretin-receptor-agonist studies, and several selective anti-myostatin and ActRII-targeted biologics are in active clinical trials — but ACE-031 itself remains a research-only reagent with no approved status anywhere.
Conclusion
ACE-031 is a well-characterized ActRIIB-Fc ligand trap whose value in the laboratory lies in its ability to block myostatin/GDF-11/activin signaling at the receptor level with a single reagent — a pharmacological alternative to genetic knockout for studying the SMAD2/3 muscle-mass axis. Its clinical history is equally instructive as a case study in target promiscuity: the same multi-ligand binding that makes it a potent research tool is the most likely explanation for the vascular findings that ended its development. Given the documented misidentification of research-channel material, construct verification should be treated as part of the experiment, not an afterthought.
Frequently Asked Questions
What is ACE-031?
ACE-031 (ramatercept) is a recombinant fusion protein combining the extracellular ligand-binding domain of the human activin type IIB receptor (ActRIIB/ACVR2B) with the Fc region of human IgG1. It acts as a soluble decoy receptor that sequesters myostatin (GDF-8), GDF-11, and activins before they can signal through cell-surface ActRIIB.
Is ACE-031 a peptide?
No. It is a glycosylated recombinant fusion protein that assembles as a disulfide-linked homodimer; published analytical work places the reduced monomer near 58 kDa. It is routinely catalogued alongside synthetic research peptides, but its size, structure, and handling requirements are those of a biologic, not a peptide.
What ligands does ACE-031 bind?
Myostatin (GDF-8) is the primary target, but the ActRIIB ectodomain also binds GDF-11, activin A, and related TGF-β superfamily ligands. A 2005 PNAS study demonstrated this directly: soluble ActRIIB still increased muscle mass in myostatin-null mice, proving that ligands other than myostatin are captured.
Why were the ACE-031 clinical trials stopped?
The phase 2 Duchenne muscular dystrophy trial was halted after the second dosing regimen due to epistaxis and telangiectasias — vascular findings unrelated to muscle. These are generally attributed in the literature to ActRIIB's participation in BMP9/BMP10–ALK1 signaling, which maintains endothelial quiescence. Development ended in 2013.
Is there recent research on ACE-031?
Yes. A February 2026 PLOS ONE study in common marmosets — the first non-human-primate dataset for the compound — reported increased lean body mass, increased cross-sectional area in both type I and type II fibers of the biceps brachii, and increased absolute and specific force in ex-vivo contractile testing after 14 weeks.
How should ACE-031 be handled in the laboratory?
As a fusion protein rather than a peptide: store the lyophilate at −20 °C or below, reconstitute gently without vortexing, aliquot to avoid freeze–thaw cycles, store reconstituted material at −80 °C for long-term use, and check for aggregation before quantitative assays.
How is the identity of ACE-031 material confirmed?
Through orthogonal protein methods: SDS-PAGE under reducing and non-reducing conditions, Western blot against both ActRIIB and human IgG Fc, and mass spectrometry. A 2025 Drug Testing and Analysis study found that 12 of 14 research-channel products contained full-length human activin receptor IIB rather than the ACE-031 Fc-fusion, underscoring why independent identity confirmation matters.
What is the purity level of Dynamite Research Peptides' ACE-031?
Our ACE-031 is listed at 99%+ purity, verified by analytical testing. Detailed data is provided on the Certificate of Analysis (COA) available for the product.
All products are for research use only — not for human or animal consumption. Nothing in this article describes, recommends, or endorses any human, clinical, therapeutic, or dietary application, and no dosing guidance for any living subject is provided or implied.